The effects of AST-120 on chronic kidney disease progression in the United States of America: a post hoc subgroup analysis of randomized controlled trials

BACKGROUND: The orally administered spherical carbon adsorbent AST-120 is used on-label in Asian countries to slow renal disease progression in patients with progressive chronic kidney disease (CKD). Recently, two multinational, randomized, double-blind, placebo-controlled, phase 3 trials (Evaluatin...

Descripción completa

Detalles Bibliográficos
Autores principales: Schulman, Gerald, Berl, Tomas, Beck, Gerald J., Remuzzi, Giuseppe, Ritz, Eberhard, Shimizu, Miho, Shobu, Yuko, Kikuchi, Mami
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045594/
https://www.ncbi.nlm.nih.gov/pubmed/27716149
http://dx.doi.org/10.1186/s12882-016-0357-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045594/
https://www.ncbi.nlm.nih.gov/pubmed/27716149
http://dx.doi.org/10.1186/s12882-016-0357-9

Ejemplares similares